Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evommune (EVMN) Net Margin (2024 - 2025)

Evommune (EVMN) has disclosed Net Margin for 2 consecutive years, with 138611.11% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 4135229.0% to 138611.11% in Q3 2025 year-over-year; TTM through Dec 2025 was 220315.38%, a N/A change, with the full-year FY2025 number at 598.45%, up 35595.0% from a year prior.
  • Net Margin was 138611.11% for Q3 2025 at Evommune, up from 97258.82% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 138611.11% in Q3 2025 to a low of 97258.82% in Q3 2024.